U.S. General Services Administration Renews Beam Global Contract Through 2030
BEAMBeam Global’s GSA contract renewed through 2030 with Cooperative Purchasing expanding access to federal, state & local agencies.
August 26, 2025Contracts
Read more →Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
BEAMBeam Therapeutics Inc. (Nasdaq: BEAM) management will be participating in several healthcare investor conferences in September
August 25, 2025Investor
Read more →Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease
BEAMCAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD).
August 14, 2025Regulatory
Read more →The FDA Has Granted Orphan Drug Designation To Beam Therapeutics' Beam-101, An Investigational Genetically Modified Cell Therapy For Sickle Cell Disease
BEAMJune 3, 2025
Read more →Beam Therapeutics Receives FDA Orphan Drug Designation For BEAM-302, A Base Editing Therapy Targeting Alpha-1 Antitrypsin Deficiency
BEAMMay 29, 2025
Read more →Beam Therapeutics To Present New Data From BEAM-101 Program iI Sickle Cell Disease At European Hematology Association 2025 Congress
BEAMMay 14, 2025
Read more →Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy Designation Has Been Granted To BEAM-302 For The Treatment Of Alpha-1 Antitrypsin Deficiency
BEAMMay 12, 2025
Read more →Guggenheim Maintains Buy on Beam Therapeutics, Lowers Price Target to $55
BEAMMay 7, 2025
Read more →Wells Fargo Maintains Overweight on Beam Therapeutics, Lowers Price Target to $70
BEAMMay 7, 2025
Read more →10 Analysts Assess Beam Therapeutics: What You Need To Know
BEAMMay 7, 2025
Read more →Barclays Maintains Equal-Weight on Beam Therapeutics, Lowers Price Target to $25
BEAMMay 7, 2025
Read more →Beam Therapeutics Q1 GAAP EPS $(1.24) Misses $(1.21) Estimate, Sales $7.47M Miss $14.87M Estimate
BEAMMay 6, 2025
Read more →Wolverine World Wide, Pacira BioSciences And Other Big Stocks Moving Higher On Monday
BEAMApril 21, 2025
Read more →Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease
BEAMBeam Therapeutics shared updated BEAM-302 trial data in AATD and plans U.S. site activation following FDA clearance of its IND
April 7, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
BEAMApril 7, 2025
Read more →Reported Saturday, Beam Therapeutics Reports 91% Mean Correction Of Circulating AAT Protein At Day 28 In BEAM-302 Phase 1/2 Trial For AATD
BEAMApril 7, 2025
Read more →Beyond The Numbers: 9 Analysts Discuss Beam Therapeutics Stock
BEAMMarch 28, 2025
Read more →B of A Securities Upgrades Beam Therapeutics to Buy, Maintains Price Target to $42
BEAMMarch 28, 2025
Read more →Beam Therapeutics Announces Clearance Of Investigational New Drug Application For BEAM-302 For Treatment Of Alpha-1 Antitrypsin Deficiency By The U.S. FDA
BEAMMarch 27, 2025
Read more →Cantor Fitzgerald Reiterates Overweight on Beam Therapeuticsto Overweight
BEAMMarch 12, 2025
Read more →Scotiabank Upgrades Beam Therapeutics to Sector Outperform, Announces $40 Price Target
BEAMMarch 10, 2025
Read more →Jones Trading Upgrades Beam Therapeutics to Buy, Announces $34 Price Target
BEAMMarch 10, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
BEAMMarch 10, 2025
Read more →Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity
BEAMBeam Therapeutics reports Phase 1/2 trial data showing BEAM-302's potential in AATD treatment, with dose-dependent mutation correction and sustained effects.
March 10, 2025
Read more →Beam Therapeutics Priced Underwritten Offering Of 16.15M Shares At $28.48 Per Share, And Pre-funded Warrants To Purchase 1.40M Shares At $28.47 Per Pre-funded Warrant, With Gross Proceeds Of Of Approximately $500M
BEAMMarch 10, 2025
Read more →Beam Therapeutics Announced Initial Safety And Efficacy Data From Its Phase 1/2 Trial Of BEAM-302, As Potential Treatment For Alpha-1 Antitrypsin Deficiency And For In Vivo Base Editing
BEAMMarch 10, 2025
Read more →Scotiabank Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $25
BEAMMarch 3, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target
BEAMFebruary 28, 2025
Read more →Analyst Expectations For Beam Therapeutics's Future
BEAMFebruary 27, 2025
Read more →Guggenheim Reiterates Buy on Beam Therapeutics, Maintains $78 Price Target
BEAMFebruary 27, 2025
Read more →RBC Capital Maintains Sector Perform on Beam Therapeutics, Raises Price Target to $26
BEAMFebruary 26, 2025
Read more →Beam Therapeutics Q4 2024 GAAP EPS $(1.09) Beats $(1.18) Estimate, Ended Fourth Quarter 2024 with $850.7M in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support Operating Plans into 2027
BEAMFebruary 25, 2025
Read more →Beam Therapeutics Expects Cash Runway To Support Operating Plans Into 2027, Now Inclusive Of Commercial Readiness Activities For BEAM-101
BEAMJanuary 13, 2025
Read more →RBC Capital Maintains Sector Perform on Beam Therapeutics, Lowers Price Target to $24
BEAMNovember 6, 2024
Read more →Breaking Down Beam Therapeutics: 5 Analysts Share Their Views
BEAMNovember 6, 2024
Read more →This Clorox Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Wednesday
BEAMNovember 6, 2024
Read more →Leerink Partners Upgrades Beam Therapeutics to Outperform, Raises Price Target to $39
BEAMNovember 6, 2024
Read more →Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial
BEAMBeam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and efficacy results, and progresses on Aalpha-1 Antitrypsin Deficiency
November 5, 2024
Read more →Beam Therapeutics To Present Hematology Franchise Data At ASH Annual Meeting, Including First Clinical Data For BEAM-101 In Sickle Cell Disease And Preclinical ESCAPE Findings
BEAMNovember 5, 2024
Read more →Patient In Beam Therapeutics' CRISPR Trial For Sickle Cell Disease Dies From Likely Chemotherapy Complications; Early Signs Of Gene Editing Effectiveness Observed In Other Participants
BEAMNovember 5, 2024
Read more →Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027
BEAMNovember 5, 2024
Read more →Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate
BEAMNovember 5, 2024
Read more →Beam Therapeutics's Earnings: A Preview
BEAMNovember 4, 2024
Read more →Beam Therapeutics to Present New Preclinical Data from Base Editing Pipeline at ASGCT 25th Annual Meeting
BEAMMay 2, 2022
Read more →Credit Suisse Initiates Coverage On Beam Therapeutics with Neutral Rating, Announces Price Target of $62
BEAMApril 28, 2022
Read more →